Follow Us:Respiratio 2017; 7 (1-2): 30-37
UTICAJ EGFR MUTACIJSKOG STATUSA NA KLINIČKI TOK BOLESTI U PACIJENATA SA ADENOKARCINOMOM PLUĆA
Lora Novaković Lacković¹, Ljilja Tadić Latinović², Мirko Stanetić¹, Marinko Vučić¹, Dušan
Janičić³
¹Klinika za plućne bolesti Univerzitetski klinički centar ,Banja Luka, Bosna i Hercegovina
²Zavod za patologiju Univerzitetski klinički centar , Banja Luka, Bosna i Hercegovina
³Služba za torakalnu hirurgiju Univerzitetski klinički centar, Banja Luka, Bosna i Hercegovina
Original Research
Naučni članak
SAŽETAK
Molekularna patologija adenokarcinoma pluća, vjerovatno je bolje definisana u odnosu na druge vrste tumora, zbog njegove učestalosti, hirurške pristupačnosti ali i zbog uspjeha u identifikovanju klinički važnih mutacija u ovoj vrsti karcinoma. EGFR (engl. Epidermal Growth Factor Receptor) mutacije su do sada klinički najrelevantnije mutacije u plućnom karcinomu, te bitan prediktivni marker za terapiju ciljnim hemoterapeuticima.
Transmembranski glikoprotein iz grupe receptora epidermalnog faktora rasta je prisutan u 10% do 15% slučajeva uznapredovalog nemikrocelularnog karcinoma pluća. Ispitivanjem je obuhvaćeno 29. pacijenata kojima je u periodu od maja 2012. godine do decembra 2016. godine u Klinici za plućne bolesti UKC RS proveden dijagnostički i terapijski tretman adenokarcinoma pluća. Kod svih pacijenata je citološki i/ili histološki potvrđen adenokarcinom pluća, a u Zavodu za patologiju UKC RS je provedeno dodatno molekularno testiranje postojećeg materijala. Studija potvrđuje navode literature o dominatnosti histološkog tipa adenokarcinoma te češćoj pojavnostiu ženskoj populaciji i u kategoriji nepušača. Studija pokazuje da su srednje vrijeme trajanja tretmana inhibitorima tirozin kinaze kao i srednje vrijeme preživljavanja duži od godinu dana.
Ključne riječi: adenokarcinom pluća, tumor, mutacija, EGFR.
LITERATURA:
|
1. Baslega J. Why the Epidermal Growth Factor Receptor? The Rational for Cancer Therapy. Oncologist 2002;7:2-8, |
|
|
|
|
|
2. Bishop J.M.: The molecular genetics of cancer. Science 235: 305-311, 1987, |
|
|
|
|
|
3. Phuong Khanh HM. Edwards SK. New Biological Agents in the Treatmant of Advanced Non- Small Cell Lung Cancer. Semin Respir Crit Care Med 2005;26 (3):323-332, |
|
|
|
|
|
4. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57(1):43-66, |
|
|
|
|
|
5. Shibuya K, Fujisaw t, Hoshino H, et al. Fluorescence bronhoscopy in the detection of preinvasive bronchial lesions in patients with sputum cytology suspicious or positive for malignancy. Lung Cancer 2001;32(1):19-25, |
|
|
|
|
|
6. Sato M, Sakurada A, Sagawa M, et al. Diagnostic results before and after introduction of autofluorescence bronhoscopy in patients suspected of having lung cancer detected by sputum cytology in lung cancer mass screening. Lung Cancer 2001;32(3):247-253, |
|
|
|
|
|
7. Stenbygaard LE, Sorensen JB, Olsen JE. Metastatic pattern in adenocarcinoma of the lung. An autopsy study from a cohort of 137 consecutive patients with complete resection. J Thorac Cardiovasc Surg 1995;110:1130-1135, |
|
|
|
|
|
8. Croce CM. Oncogenes and cancer. (Jan 2008.) N Engl J Med 356(5):502-511. |
|
|
|
|
|
9. Erman M. Molecular mechanisms of signal transduction: Epidermal growth factor receptor family, Vascular endothelial growth factor family, Kit, Plateled-derived growth factor receptor, Ras. Journal of BUON 2007;12(1):83-94, |
|
|
|
|
|
10. Miller VA, Riely GJ, Zakowski MF, et al. Molecular characteriistics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 2008;26:1472-1478; |
|
|
|
|
|
11. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-346, |
|
|
|
|
|
12. Tsao, M. S. et al. Erlotinib in lung cancer – molecular and clinical predictors of outcome. N Engl J Med 2005; 5, 13-144, |
|
|
|
|
|
13. Mok TS et al. Gefitinib or carboplatiin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361, 947-957., |
|
|
|
|
|
14. Schottenfeld D, Epidemiology of Lung Cancer. In: Pass HL, Mitchell JB, Johnson DH, Turrisi AT. Lung Cancer. Lippincott-Raven, Philadelphia New York,1996:305-321, |
|
|
|
|
|
15. Shibuya K, Fujisaw T, Hoshino H, et al. Fluorescence bronhoscopy in the detection of preinvasive bronchial lesions in patients with sputum cytology suspicious or positive for malignancy. Lung Cancer 2001;32(1):19-25, |
|
|
|
|
|
16. Sato M, Sakurada A, Sagawa M, et al. Diagnostic results before and after introduction of autofluorescence bronhoscopy in patients suspected of having lung cancer detected by sputum cytology in lung cancer mass screening. Lung Cancer 2001;32(3):247-253, |
|
|
|
|
|
17. Rami-Porta R, Crowley JJ, Goldstraw P (February 2009). "The revised TNM staging system for lung cancer". Annals of Thoracic and Cardiovascular Surgery 15(1):4-9. PMID 19262443, |
|
|
|
|
|
18. Philip TC, Timothy CA. Lung Cancer GenotypeBased Therapy and Predictive Biomarkers. Arch Pathol Mab Med2012;136:1482-1492, |
|
|
|
|
|
19. Kraweczyk P, Ramlau R, Chorostowska-Wynimiko J, Powrozek T, Levandovska MA, Limon J et al. The efficacy of EGFR gene mutation testing in various samples from non small cell lung cancer patients: multicentre retrospective study. J Cancer Res Clin Oncol 2015;141:61-68, |
|
|
|
|
|
20. Shim HS, Lee DH, Park EI, Kim SH. Histopatologic Characteristic of Lung Adenocarcinomas with Epiderma Growth Factor Receptor Mutation in the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Lung Adenocarcinoma Classification. Arch Pathol Lab Med 2011;135:1392-1398, |
|
|
|
|
|
21. Keedy VL, Temin S, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-smallcell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011; 29: 2121–7, |
|
|
|
|
|
22. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: e73. |
|
Submitted: April 10th, 2017
Accepted: May 10th, 2017
Kontakt osoba: Lora Novaković Lacković
Klinika za plućne bolesti UKC RS, Zdrave Korde 1
78 000 Banja Luka, Republika Srpska, BiH
This email address is being protected from spambots. You need JavaScript enabled to view it., telefon: +387 51 343 209